Jóhannes Reynisson

pharmacy researcher

Jóhannes Reynisson is …
instance of (P31):
humanQ5

External links are
P10283OpenAlex IDA5071321918
P496ORCID iD0000-0003-4174-9512
P1153Scopus author ID6603460509

P185doctoral studentChatchakorn EurtivongQ59559301
Danilo CorredduQ88210046
Ayesha ZafarQ124392441
Anna M. MatuszekQ127257388
P108employerUniversity of KeeleQ1737734
P106occupationresearcherQ1650915
P5008on focus list of Wikimedia projectNZThesisProjectQ111645234
P21sex or gendermaleQ6581097

Reverse relations

doctoral advisor (P184)
Q127257388Anna M. Matuszek
Q124392441Ayesha Zafar
Q59559301Chatchakorn Eurtivong
Q88210046Danilo Correddu

author (P50)
Q466249742,6,10-Tris(dialkylamino)trioxatriangulenium salts: a new promising fluorophore. Ion-pair formation and aggregation in non-polar solvents.
Q387265943-Amino-thieno[2,3-b]pyridines as microtubule-destabilising agents: Molecular modelling and biological evaluation in the sea urchin embryo and human cancer cells.
Q57149545A Novel Class of Tyrosyl-DNA Phosphodiesterase 1 Inhibitors That Contains the Octahydro-2-chromen-4-ol Scaffold
Q90663132Acetyl-CoA-mediated activation of Mycobacterium tuberculosis isocitrate lyase 2
Q49720564Aminoadamantanes containing monoterpene-derived fragments as potent tyrosyl-DNA phosphodiesterase 1 inhibitors.
Q40050431Anti-influenza activity of diazaadamantanes combined with monoterpene moieties
Q34048477Bond stability of the "undesirable" heteroatom-heteroatom molecular moieties for high-throughput screening libraries
Q91520982Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-5
Q46905097Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000.
Q51380847Coumarin Antifungal Lead Compounds from Millettia thonningii and Their Predicted Mechanism of Action.
Q43039962DFT calculations on the deprotonation site of the one-electron oxidised guanine-cytosine base pair
Q98202331Design, Synthesis, and Biological Investigation of Novel Classes of 3-Carene-Derived Potent Inhibitors of TDP1
Q60162743Development of NMR and thermal shift assays for the evaluation of isocitrate lyase inhibitors
Q91642873Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
Q36671457Evidence that phospholipase C is involved in the antitumour action of NSC768313, a new thieno[2,3-b]pyridine derivative
Q48176143Ferrocenyl Paclitaxel and Docetaxel Derivatives: Impact of an Organometallic Moiety on the Mode of Action of Taxanes.
Q47274809GPCR Modulation of Thieno[2,3-b]pyridine Anti-Proliferative Agents.
Q64268874Generation of Quality Hit Matter for Successful Drug Discovery Projects
Q37712277Glycophenotype of breast and prostate cancer stem cells treated with thieno[2,3-b]pyridine anticancer compound
Q38910350Half-sandwich ruthenium(II) biotin conjugates as biological vectors to cancer cells
Q46953316Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases
Q44760687Hydrogen bonding between histidine and lignin model compounds or redox mediators as calculated with the DFT method. Effects on the ease of oxidation
Q91254000Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)
Q38765080Identification of anticancer agents based on the thieno[2,3-b]pyridine and 1H-pyrazole molecular scaffolds
Q27662513Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate
Q38357617Intercalation of trioxatriangulenium ion in DNA: binding, electron transfer, x-ray crystallography, and electronic structure.
Q47720805Investigation into Improving the Aqueous Solubility of the Thieno[2,3-b]pyridine Anti-Proliferative Agents.
Q33359104Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds
Q42733678Molecular mechanism of base pairing infidelity during DNA duplication upon one-electron oxidation
Q46489626Mutagenic potential of nitrenium ions of nitrobenzanthrones: correlation between theory and experiment
Q39796289Mutagenicity and DNA adduct formation by the urban air pollutant 2-nitrobenzanthrone
Q48206344New Anti-Seizure (Arylalkyl)azole Derivatives: Synthesis, In Vivo and In Silico Studies.
Q48172023New Iminodiacetate-Thiosemicarbazone Hybrids and Their Copper(II) Complexes Are Potential Ribonucleotide Reductase R2 Inhibitors with High Antiproliferative Activity
Q51473584New inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 7-hydroxycoumarin and monoterpenoid moieties.
Q52644553Novel Semisynthetic Derivatives of Bile Acids as Effective Tyrosyl-DNA Phosphodiesterase 1 Inhibitors.
Q33507355One-electron reduction of 2-aminopurine in the aqueous phase. A DFT and pulse radiolysis study
Q33267467Photoionization versus photoheterolysis of all-trans-retinol. The effects of solvent and laser radiation intensity
Q44375445Photophysics of trioxatriangulenium ion. electrophilic reactivity in the ground state and excited singlet state.
Q31112620Radical Chemistry and Cytotoxicity of Bioreductive 3-Substituted Quinoxaline Di-N-Oxides
Q40368701Serendipity in anticancer drug discovery
Q47321477Size estimation of chemical space: how big is it?
Q27664427Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells
Q51260441Synthesis and antiproliferative activity of 2-chlorophenyl carboxamide thienopyridines.
Q38300174Synthesis and biological evaluation of novel tyrosyl-DNA phosphodiesterase 1 inhibitors with a benzopentathiepine moiety
Q38959142Synthesis and cytotoxicity of thieno[2,3-b]pyridine and furo[2,3-b]pyridine derivatives
Q38795823Synthesis and cytotoxicity of thieno[2,3-b]quinoline-2-carboxamide and cycloalkyl[b]thieno[3,2-e]pyridine-2-carboxamide derivatives.
Q46302107Synthesis and in vitro Biological Evaluation of Ferrocenyl Side-Chain-Functionalized Paclitaxel Derivatives.
Q47196925Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action
Q47159745Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action† †Electronic supplementary information (ESI) available: Experimental, crystallographic, biological and mass spectrometric data, full list of pr
Q57804631The Development of a Weighted Index to Optimise Compound Libraries for High Throughput Screening
Q100392868The First Berberine-Based Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), an Important DNA Repair Enzyme
Q99579575The cytotoxic potential of cationic triangulenes against tumour cells
Q39331377The effect of PLC-γ2 inhibitors on the growth of human tumour cells
Q39870054The identification of novel PLC-gamma inhibitors using virtual high throughput screening
Q43504556The physicochemical properties of a new class of anticancer fungal polysaccharides: a comparative study
Q45232748Tuning of hydrogen bond strength using substituents on phenol and aniline: a possible ligand design strategy
Q112575813Validating TDP1 as an Inhibition Target for the Development of Chemosensitizers for Camptothecin-Based Chemotherapy Drugs
Q38787832Virtual screening and biophysical studies lead to HSP90 inhibitors.
Q36091191Wine Compounds as a Source for HTS Screening Collections. A Feasibility Study

thesis committee member (P9161)
Q112938893Application and development of in silico methods in drug discovery
Q112906238Defining Known Drug Space by DFT based molecular descriptors. Virtual screening for novel Atg5-Atg16 complex inhibitors for autophagy modulation.
Q112888462Definition of Drug-like Chemical Space Based on Calculation of Heteroatom-Heteroatom Bond Stability by using Density Functional Theory
Q112947586Definition of Known Drug Space - Analysing Known Drug Space using the Potential Energy Surface as a Possible Molecular Descriptor
Q112888759Identification of Lead Compounds for the Chk1 Kinase and PLC-γ2
Q112931966In Silico Design and Discovery of Antifungal, Anticancer and Antimalarial Drug Candidates
Q111963335In silico approaches in Drug Discovery and Development of Anticancer Drug Candidates
Q112886211Molecular Modelling and Anti-Cancer Drug Design - A Closer Inspection of PLC-gamma
Q112889557Predicting the Cytochrome P450 Mediated Major Metabolic Site of Drug-like Compounds using Carbon-Hydrogen Bond Dissociation Energies
Q112907760Rongoā: Māori Medicine. A Modern Perspective - Physicochemical Parameters
Q111963453Studies on Human Proteins Involved in Deregulated Translation in Parkinson's disease
Q112933309Synthetic Studies and Molecular Modelling of Pyrido[3,4-b]indole-derivatives as potential PC-PLC Inhibitors
Q112900431Synthetic Studies and Molecular Modelling of Thieno[2,3-b]pyridine-3-amine-derivatives as PLC Inhibitors
Q112886754The acceptable region in drug-like chemical space for the aromatic amine/nitro compounds based on the stability of nitrenium ions
Q112947825The physicochemical properties of veterinary pharmaceuticals; establishing veterinary drug-like space
Q112909682The physiochemical parameters of bioactive compounds in medicinal New Zealand plants
Q112930707Virtual screening of natural products

Search more.